Dr. Szilard Kiss

The popular diabetes and weight-loss medication tirzepatide (brand name Mounjaro or Zepbound) may lower the risk of diabetic retinopathy, a leading cause of vision loss, according to Weill Cornell Medicine investigators. The findings may offer comfort to patients concerned about their eye health while taking the drug.

Weill Cornell Medicine faculty members were honored with awards for their exemplary achievements in medical research, education and care May 14-15 during Weill Cornell Medicine’s commencement activities.

Weill Cornell Medicine has received a $1.27 million grant from the United States Department of Defense (DoD) to develop treatment for a rare but devastating eye condition largely affecting military personnel who suffer traumatic eye injuries in combat.